Zaid Admani

Novo Nordisk, which is the company behind Ozempic and WeGovie, launched a pill version of WeGovie back in January.

So now the competition is going to heat up between the two companies.

Both pills are going to start at $149 a month.

Novo Nordisk has just fumbled the bag when it comes to the GLP-1 space.

And they kind of kicked off the category with Ozempic.

But despite being first there and being first when it comes to their pills, the company's stock has been struggling.

Novo Nordisk stock is down around 30% this

Now, Eli Lilly has also struggled a bit.

Their stock is down around 12% this year.

So I'm definitely keeping my eye on this space.

And I'm curious to see if the introduction of these GLP-1 pills will meaningfully increase the market size for these drugs.

Let's talk about some stocks making moves today.

Shares of Star Surgical are soaring after the EyeSight tech company reported preliminary results for Q1 showing about 110% growth year over year.

See, Star makes these implantable contact lenses called EVO-ICL.

These are permanent lenses that get surgically placed inside your eye.

And for most patients, you walk out with 20-20 vision.

Now, fun fact here, I actually got ICL surgery about a year and a half ago because I was so nearsighted that I couldn't even qualify for LASIK.

The surgeon implanted this Evo contact lens in my eye, and I have 20-20 vision now.

It was an expensive surgery, but it was quick, and I got to say it was totally worth it because it's been life-changing for me.

Star Surgical got FDA approval back in 2022, and they're seeing a big boost in the U.S.